Several receptor-specific and pan-FGFR inhibitors have been developed and tested in clinical trials, either alone or in combination with other drugs [41]; however, they showed little success in ER + breast cancers with FGFR1 amplification [42]. This evidence concerns the gene ESR1 and breast cancer.